ProgenyHealth is the only company in the United States whose sole focus is the management of the care and support of infants hospitalized in the neonatal intensive care unit, as well as during the important months after their discharge from the hospital. We are privileged to work with over 1,400 NICUs across the US, with our board-certified neonatologists and pediatricians interacting and collaborating with the attending physicians and hospital-based teams to drive the best possible health outcome for each child.
ProgenyHealth is committed to helping providers everywhere with one of the most devastating aspects of the opioid crisis: neonatal abstinence syndrome (NAS). With our newly updated Best Practices for Management of Infants with NAS, our clinical team has addressed major issues affecting these babies and their families.
From 2004-2013, the incidence of NAS and maternal opioid use in the United States increased disproportionately in rural counties from 12.9% in 2003/2004 to 21.2% in 2012/20131.
ProgenyHealth’s team of neonatologists, pediatric nurses, and social workers have managed over 65,000 NICU cases to-date as part of our neonatal medical management service offering. Infants born with neonatal abstinence syndrome (NAS) – symptoms related to opioid exposure in the womb – represent a complex and growing segment of this population. Tackling their unique challenges requires a specialized approach that supports the needs of both the mother and the baby.
In our recently updated Best Practices for Management of Infants with Neonatal Abstinence Syndrome (NAS), ProgenyHealth addressed major issues affecting these babies and their families. This new document was researched and developed by the clinical team at ProgenyHealth, which includes neonatologists and pediatricians. The contents were then reviewed and approved by our Medical Advisory Board, a committee of practicing neonatologists from many regions across the U.S., to assure both scientific accuracy and consistency with current clinical practice patterns.
With our updated Best Practices for Management of Infants with Neonatal Abstinence Syndrome (NAS), ProgenyHealth addresses some of the newest treatment methods, medication doses, transition of care needs, and long-term concerns for these infants.
Neonatal drug withdrawal can occur when newborn infants are exposed to medications or addictive substances in-utero or can occur following prolonged postnatal exposure.
October marks Neonatal Abstinence Syndrome (NAS) Awareness Month. NAS is the result of the sudden discontinuation of fetal exposure of a substance, typically an opiate such as methadone, heroin, or prescription opiates. It can give afflicted newborns a constellation of symptoms such as: vomiting, loose stools, high-pitched crying, irritability, inconsolability, tremors, sweating, sneezing, poor feeding, or even seizures.
Because of the opioid epidemic in the United States, the incidence of NAS has skyrocketed over the past decade. For the NICU physicians and nurses that care for such unfortunate infants on a regular basis, following best practices for NAS care is crucial.
When I joined ProgenyHealth as a Medical Director, one of the aspects of the job that I found most appealing was the ability to do meaningful outreach with other neonatologists across the country. Having taken care of many medically complex babies as an attending physician in a NICU for over eight years, I believe I have a good understanding of what physicians in the community are going through and the challenges they are facing.